Cargando…

Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort

PURPOSE: To describe ocular manifestations of acute leukemia in a Tunisian cohort and to assess the associations between ophthalmic findings and epidemiological, clinical, and biological features of the disease. METHODS: A prospective study included patients newly diagnosed with acute leukemia refer...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayadi, Jihene, Gouider, Dhouha, Allouche, Yasmine, Choura, Racem, Cherni, Ines, Sayadi, Malek, Benneji, Hend, Zghal, Imene, Malek, Ines, Nacef, Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560867/
https://www.ncbi.nlm.nih.gov/pubmed/36249442
http://dx.doi.org/10.2147/OPTH.S365648
_version_ 1784807848007434240
author Sayadi, Jihene
Gouider, Dhouha
Allouche, Yasmine
Choura, Racem
Cherni, Ines
Sayadi, Malek
Benneji, Hend
Zghal, Imene
Malek, Ines
Nacef, Leila
author_facet Sayadi, Jihene
Gouider, Dhouha
Allouche, Yasmine
Choura, Racem
Cherni, Ines
Sayadi, Malek
Benneji, Hend
Zghal, Imene
Malek, Ines
Nacef, Leila
author_sort Sayadi, Jihene
collection PubMed
description PURPOSE: To describe ocular manifestations of acute leukemia in a Tunisian cohort and to assess the associations between ophthalmic findings and epidemiological, clinical, and biological features of the disease. METHODS: A prospective study included patients newly diagnosed with acute leukemia referred to our clinics between January 2019 and July 2020. All patients underwent a complete ophthalmic evaluation and spectral-domain optical coherence tomography (SD-OCT) at presentation, then every two months during one year. We defined two groups: Group 1 included patients with leukemic ophthalmopathy and group 2 included patients with normal ophthalmic examination. RESULTS: Forty-six patients were enrolled. The mean age of patients was 32.1±15.3 years. The sex ratio M/F was 1.55 (28 male patients and 18 females). Twenty-nine patients (63%) had acute myeloid leukemia (AML), and 17 (37%) had acute lymphoblastic leukemia (ALL). The average follow-up was 9.1 months (range: 3–12 months). We observed ophthalmic manifestations in 28 patients (61%). Among them, 17 (61%) had vision-threatening complications. The posterior segment was the most common site of ocular involvement (82% of group1). Primary leukemic infiltration (Disc edema, ptosis, exophthalmos) was present in 13 eyes (14.1%). Twenty-seven eyes (29.3%) had secondary involvement lesions (Subconjunctival hemorrhage, periorbital ecchymosis, retinal/sub-hyaloid hemorrhage, dilated/tortuous veins). Twenty-one eyes (22.8%) showed other ocular manifestations which etiopathogenesis is not yet fully understood (White-centred hemorrhages, cotton-wool spots, serous retinal detachment, hemorrhagic pigment epithelial detachment). Leukemic retinopathy was significantly more frequent in adults (23/39 and 1/7 in adult and pediatric groups, respectively; p=0.003). Patients suffering from AML were more likely to have secondary ocular involvement (20/29 and 7/17 in AML and ALL patients, respectively; p=0.047). Retinal hemorrhages were statistically associated with anemia and thrombocytopenia (p=0.041 and p=0.034; respectively). CONCLUSION: Leukemic ophthalmopathy seems to be frequent and may lead to severe visual impairment. An ophthalmic assessment complemented with SD-OCT has paramount importance in all newly diagnosed acute leukemic patients.
format Online
Article
Text
id pubmed-9560867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95608672022-10-15 Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort Sayadi, Jihene Gouider, Dhouha Allouche, Yasmine Choura, Racem Cherni, Ines Sayadi, Malek Benneji, Hend Zghal, Imene Malek, Ines Nacef, Leila Clin Ophthalmol Original Research PURPOSE: To describe ocular manifestations of acute leukemia in a Tunisian cohort and to assess the associations between ophthalmic findings and epidemiological, clinical, and biological features of the disease. METHODS: A prospective study included patients newly diagnosed with acute leukemia referred to our clinics between January 2019 and July 2020. All patients underwent a complete ophthalmic evaluation and spectral-domain optical coherence tomography (SD-OCT) at presentation, then every two months during one year. We defined two groups: Group 1 included patients with leukemic ophthalmopathy and group 2 included patients with normal ophthalmic examination. RESULTS: Forty-six patients were enrolled. The mean age of patients was 32.1±15.3 years. The sex ratio M/F was 1.55 (28 male patients and 18 females). Twenty-nine patients (63%) had acute myeloid leukemia (AML), and 17 (37%) had acute lymphoblastic leukemia (ALL). The average follow-up was 9.1 months (range: 3–12 months). We observed ophthalmic manifestations in 28 patients (61%). Among them, 17 (61%) had vision-threatening complications. The posterior segment was the most common site of ocular involvement (82% of group1). Primary leukemic infiltration (Disc edema, ptosis, exophthalmos) was present in 13 eyes (14.1%). Twenty-seven eyes (29.3%) had secondary involvement lesions (Subconjunctival hemorrhage, periorbital ecchymosis, retinal/sub-hyaloid hemorrhage, dilated/tortuous veins). Twenty-one eyes (22.8%) showed other ocular manifestations which etiopathogenesis is not yet fully understood (White-centred hemorrhages, cotton-wool spots, serous retinal detachment, hemorrhagic pigment epithelial detachment). Leukemic retinopathy was significantly more frequent in adults (23/39 and 1/7 in adult and pediatric groups, respectively; p=0.003). Patients suffering from AML were more likely to have secondary ocular involvement (20/29 and 7/17 in AML and ALL patients, respectively; p=0.047). Retinal hemorrhages were statistically associated with anemia and thrombocytopenia (p=0.041 and p=0.034; respectively). CONCLUSION: Leukemic ophthalmopathy seems to be frequent and may lead to severe visual impairment. An ophthalmic assessment complemented with SD-OCT has paramount importance in all newly diagnosed acute leukemic patients. Dove 2022-10-14 /pmc/articles/PMC9560867/ /pubmed/36249442 http://dx.doi.org/10.2147/OPTH.S365648 Text en © 2022 Sayadi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sayadi, Jihene
Gouider, Dhouha
Allouche, Yasmine
Choura, Racem
Cherni, Ines
Sayadi, Malek
Benneji, Hend
Zghal, Imene
Malek, Ines
Nacef, Leila
Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
title Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
title_full Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
title_fullStr Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
title_full_unstemmed Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
title_short Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
title_sort ophthalmic manifestations of newly diagnosed acute leukemia patients in a tunisian cohort
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560867/
https://www.ncbi.nlm.nih.gov/pubmed/36249442
http://dx.doi.org/10.2147/OPTH.S365648
work_keys_str_mv AT sayadijihene ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT gouiderdhouha ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT alloucheyasmine ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT chouraracem ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT cherniines ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT sayadimalek ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT bennejihend ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT zghalimene ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT malekines ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort
AT nacefleila ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort